Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia
Standard
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia. / Mellinghoff, Sibylle C; Robrecht, Sandra; Sprute, Rosanne; Mayer, Leonie; Weskamm, Leonie M; Dahlke, Christine; Gruell, Henning; Teipel, Finn; Schlößer, Hans A; Siepmann, Klara; Thelen, Martin; Fink, Anna-Maria; Fischer, Kirsten; Klein, Florian; Addo, Marylyn M; Kolovou, Androniki; Cornely, Oliver A; Eichhorst, Barbara; Hallek, Michael; Langerbeins, Petra.
In: EUR J HAEMATOL, Vol. 112, No. 5, 05.2024, p. 788-793.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia
AU - Mellinghoff, Sibylle C
AU - Robrecht, Sandra
AU - Sprute, Rosanne
AU - Mayer, Leonie
AU - Weskamm, Leonie M
AU - Dahlke, Christine
AU - Gruell, Henning
AU - Teipel, Finn
AU - Schlößer, Hans A
AU - Siepmann, Klara
AU - Thelen, Martin
AU - Fink, Anna-Maria
AU - Fischer, Kirsten
AU - Klein, Florian
AU - Addo, Marylyn M
AU - Kolovou, Androniki
AU - Cornely, Oliver A
AU - Eichhorst, Barbara
AU - Hallek, Michael
AU - Langerbeins, Petra
N1 - © 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2024/5
Y1 - 2024/5
N2 - OBJECTIVE: Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL).METHODS/RESULTS: Blood samples of six patients with CLL were collected 55 days after fourth COVID-19 vaccination. All patients had a SARS-CoV-2 infection within 12 months before the second booster (fourth vaccination). SARS-CoV-2 spike receptor binding domain (RBD)-specific IgG antibodies were detectable in 6/6 (100.0%) CLL patients after four compared to 4/6 (66.7%) after three vaccinations. The median number of SARS-CoV-2 spike-specific T cells after repeated booster vaccination plus infection was 166 spot-forming cells (SFC) per million peripheral blood mononuclear cells. Overall, 5/5 (100%) studied patients showed a detectable increase in T cell activity.CONCLUSION: Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID-19 vaccination combined with SARS-CoV-2 infection, even in those undergoing B cell-depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.
AB - OBJECTIVE: Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL).METHODS/RESULTS: Blood samples of six patients with CLL were collected 55 days after fourth COVID-19 vaccination. All patients had a SARS-CoV-2 infection within 12 months before the second booster (fourth vaccination). SARS-CoV-2 spike receptor binding domain (RBD)-specific IgG antibodies were detectable in 6/6 (100.0%) CLL patients after four compared to 4/6 (66.7%) after three vaccinations. The median number of SARS-CoV-2 spike-specific T cells after repeated booster vaccination plus infection was 166 spot-forming cells (SFC) per million peripheral blood mononuclear cells. Overall, 5/5 (100%) studied patients showed a detectable increase in T cell activity.CONCLUSION: Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID-19 vaccination combined with SARS-CoV-2 infection, even in those undergoing B cell-depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.
KW - Humans
KW - SARS-CoV-2
KW - Leukemia, Lymphocytic, Chronic, B-Cell/complications
KW - COVID-19
KW - COVID-19 Vaccines
KW - Leukocytes, Mononuclear
KW - Immunoglobulin G
KW - Postoperative Complications
KW - Vaccination
KW - Adaptive Immunity
KW - Antibodies, Viral
U2 - 10.1111/ejh.14170
DO - 10.1111/ejh.14170
M3 - SCORING: Journal article
C2 - 38311570
VL - 112
SP - 788
EP - 793
JO - EUR J HAEMATOL
JF - EUR J HAEMATOL
SN - 0902-4441
IS - 5
ER -
